The Endothelin Receptor Antagonist Macitentan Inhibits Human Cytomegalovirus Infection. [PDF]
Cells, 2021 Human cytomegalovirus (HCMV) infection is an important cause of morbidity and mortality in immunocompromised patients and a major etiological factor for congenital birth defects in newborns.
Landázuri N +6 more
europepmc +2 more sources
Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension. [PDF]
Hypertension, 2020 Supplemental Digital Content is available in the text. This study examined the dose-response characteristics of aprocitentan, a dual endothelin A/endothelin B receptor antagonist, in patients with essential hypertension.
Verweij P +4 more
europepmc +2 more sources
The endothelin receptor antagonist macitentan ameliorates endothelin-mediated vasoconstriction and promotes the survival of retinal ganglion cells in rats. [PDF]
Front Ophthalmol (Lausanne), 2023 Glaucoma is a chronic and progressive eye disease, commonly associated with elevated intraocular pressure (IOP) and characterized by optic nerve degeneration, cupping of the optic disc, and loss of retinal ganglion cells (RGCs).
Kodati B +13 more
europepmc +2 more sources
Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: A safe and effective therapy? [PDF]
Gastroenterology, 2005 BACKGROUND & AIMS Portopulmonary hypertension (PPHTN), a severe complication of portal hypertension is observed in 3%-6% of patients evaluated for liver transplantation. Endothelin-1, a potent vasoconstrictor, is likely to play a role in the pathogenesis
Christian Kuntzen +2 more
openalex +2 more sources
Pipersentan: A De Novo Synthetic Endothelin Receptor Antagonist that Inhibits Monocrotaline- and Hypoxia-Induced Pulmonary Hypertension. [PDF]
Front Pharmacol, 2022 Background: Although major advances have been made in the pathogenesis and management of pulmonary arterial hypertension (PAH), the endothelin system is still considered to play a vital role in the pathology of PAH due to its vasoconstrictive action ...
Zhang Z +11 more
europepmc +2 more sources
Clinical pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist macitentan. [PDF]
Clin Pharmacokinet, 2015 Pulmonary arterial hypertension (PAH) is a progressive disease of the lung vascular system, which leads to right-sided heart failure and ultimately death if untreated. Treatments to regulate the pulmonary vascular pressure target the prostacyclin, nitric
Sidharta PN, Treiber A, Dingemanse J.
europepmc +2 more sources
Aprocitentan: A new development of resistant hypertension
The Journal of Clinical Hypertension, 2023 As the blood pressure threshold for commencing antihypertensive treatment diminishes, the cohort suffering from resistant hypertension (RH) correspondingly expands.
Yao Yao +4 more
doaj +1 more source
Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors [PDF]
Kidney Research and Clinical Practice, 2022 Progress in the treatment of diabetic kidney disease (DKD) has been modest since the early trials on renin-angiotensin-aldosterone system inhibitors (RAASis).
Anthony T. P. Chan, Sydney C. W. Tang
doaj +1 more source
Pulmonary Circulation, 2020 Many patients with pulmonary arterial hypertension do not achieve treatment goals with monotherapy, and therefore combination therapy is becoming the standard of care.
Hossein-Ardeschir Ghofrani +10 more
doaj +1 more source
Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. [PDF]
PLoS ONE, 2012 Two endothelin receptor antagonists (ERAs), bosentan and ambrisentan, are currently approved for the treatment of pulmonary arterial hypertension (PAH), a devastating disease involving an activated endothelin system and aberrant contraction and ...
John Gatfield +4 more
doaj +1 more source